Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9432831 | 0.89 | MAPT (0.47) | MAPTSLC6A2SLC6A4CHRM2CHRM4 | |
| SCHEMBL8715541 | 0.77 | CYP3A4 (0.34) | MAPTSLC6A4CHRM2CHRM4CHRM3 | |
| SCHEMBL31674984 | 0.77 | RAB9A (0.35) | MAPT | |
| SCHEMBL31674982 | 0.77 | RAB9A (0.35) | MAPT | |
| SCHEMBL31674989 | 0.77 | RAB9A (0.35) | MAPT | |
| SCHEMBL823220 | 0.76 | MAPT (0.38) | MAPTSLC6A2SLC6A4CHRM2CHRM4 | |
| Water SCHEMBL27872681 | 0.74 | MAPT (0.37) | MAPTCHRM2CHRM4CHRM3 | |
| SCHEMBL4267252 | 0.71 | MAPT (0.33) | MAPT | |
| SCHEMBL9133786 | 0.71 | CHRM2 (0.53) | SLC6A2SLC6A4CHRM2CHRM4CHRM3 | |
| SCHEMBL11514730 | 0.71 | CHRM2 (0.48) | SLC6A2SLC6A4CHRM2CHRM4CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054376-A1 | BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES | PHARMOS CORPORATION | 2009-02-26 | — | — | US | disclosed |
| EP-1885709-A2 | BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES | Pharmos Corporation (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006129318-A2 | BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES | PHARMOS CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054376-A1 | BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES | CNR2, CNR1, TRPV1 | MAPT 1506/4885SLC6A2 2966/4885SLC6A4 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.